Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2025-12-25 @ 10:56 PM
Study NCT ID:
NCT04444167
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2020-06-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
Sponsor:
Akeso
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-07
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-20
Completion Date Type:
ACTUAL
First Submit Date:
2020-06-21
First Submit QC Date:
None
Study First Post Date:
2020-06-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-23
Last Update Post Date:
2024-04-25
Last Update Post Date Type:
ACTUAL